Search research articles
Contact Us
Filters
Showing results (1-10 of 56) with videos related to
Page
of 6
Sort By:
Chinese Clinical Oncology
|
April 6, 2015
Phase II design: history and evolution
Larry Rubinstein
Clinical Trials (London, England)
|
July 20, 2012
A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials
Michael W Sill, Larry Rubinstein, Samuel Litwin, et al.
Journal of the National Cancer Institute
|
June 1, 2013
Response
Sally Hunsberger, Larry Rubinstein, Scott A Boerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 12, 2009
Randomized phase II designs
Larry Rubinstein, John Crowley, Percy Ivy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2010
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee
S Percy Ivy, Lillian L Siu, Elizabeth Garrett-Mayer, et al.
Journal of the National Cancer Institute
|
November 22, 2012
Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials
Sachin Gupta, Sally Hunsberger, Scott A Boerner, et al.
Seminars in Oncology
|
September 25, 2016
Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials
Shivaani Kummar, Khanh Do, Geraldine O'Sullivan Coyne, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
August 12, 2016
Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials
Hideaki Bando, Larry Rubinstein, Pamela Harris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 3, 2017
The Challenge for Development of Valuable Immuno-oncology Biomarkers
Janice M Mehnert, Arta M Monjazeb, Johanna M T Beerthuijzen, et al.
Journal of Biopharmaceutical Statistics
|
April 23, 2009
Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience
Elisabeth I Heath, Patricia M LoRusso, S Percy Ivy, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 56) with videos related to
Sort By:
Page
of 6
Chinese Clinical Oncology
|
April 6, 2015
Phase II design: history and evolution
Larry Rubinstein
Clinical Trials (London, England)
|
July 20, 2012
A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials
Michael W Sill, Larry Rubinstein, Samuel Litwin, et al.
Journal of the National Cancer Institute
|
June 1, 2013
Response
Sally Hunsberger, Larry Rubinstein, Scott A Boerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 12, 2009
Randomized phase II designs
Larry Rubinstein, John Crowley, Percy Ivy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2010
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee
S Percy Ivy, Lillian L Siu, Elizabeth Garrett-Mayer, et al.
Journal of the National Cancer Institute
|
November 22, 2012
Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials
Sachin Gupta, Sally Hunsberger, Scott A Boerner, et al.
Seminars in Oncology
|
September 25, 2016
Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials
Shivaani Kummar, Khanh Do, Geraldine O'Sullivan Coyne, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
August 12, 2016
Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials
Hideaki Bando, Larry Rubinstein, Pamela Harris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 3, 2017
The Challenge for Development of Valuable Immuno-oncology Biomarkers
Janice M Mehnert, Arta M Monjazeb, Johanna M T Beerthuijzen, et al.
Journal of Biopharmaceutical Statistics
|
April 23, 2009
Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience
Elisabeth I Heath, Patricia M LoRusso, S Percy Ivy, et al.
Page
of 6